Person:
Leboeuf, Nicole

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Leboeuf

First Name

Nicole

Name

Leboeuf, Nicole
Author's Publications: search.filters.isAuthorOfPublication.e3401524-0d60-4035-ba04-a31cf30791ca

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
    (American Association for Cancer Research (AACR), 2016) Montero, Juan; Stephansky, Jason; Cai, Tianyu; Griffin, Gabriel; Cabal-Hierro, Lucia; Togami, Katsuhiro; Hogdal, Leah J.; Galinsky, Ilene; Morgan, Elizabeth; Aster, Jon; Davids, Matthew; Leboeuf, Nicole; Stone, Richard; Konopleva, Marina; Pemmaraju, Naveen; Letai, Anthony; Lane, Andrew
    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the anti-apoptotic protein BCL-2 and were uniformly sensitive to the BCL-2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on two patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL-2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker.
  • Thumbnail Image
    Publication
    Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature
    (BioMed Central, 2017) Song, Johanna S.; Tawa, Marianne; Chau, Nicole G.; Kupper, Thomas; Leboeuf, Nicole
    Background: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. Case presentations We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment. Conclusion: Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.